Onodera Hiroshi, Sasaki Shoji, Otake Seiji, Tomohiro Masayuki, Shibuya Kazumoto, Nomura Mamoru
Pharmaceutical & Medical Devices Agency.
J Toxicol Sci. 2015 Jun;40(3):295-307. doi: 10.2131/jts.40.295.
Humans commonly obtain approximately 80% of external information from vision. Since loss of vision markedly decreases quality of life, risk assessments for visual toxicity of new drugs are extremely important. However, the ICH S4 guideline for nonclinical toxicity study of new drugs only indicates a brief instruction for ophthalmologic examinations, and submitted data for drug approval according only to this guideline are not always considered sufficient in light of ocular toxicity risk assessments. The eye is an assembly of many specialized sub-organs which have specific functions, and its integral maintenance of homeostasis plays an important role of visual function. When only a part of integrity of functions is lost, overall function of the eye might be commonly disturbed. Therefore, understanding of anatomy and physiology of these sub-organs may help know mechanisms of observed ocular changes. In ophthalmologic examinations in nonclinical toxicity studies, it is vital to understand the principles and features of each examination. Comparisons of findings between pre and post drug treatment as well as considerations of species differences, strain differences, age differences, and location/degree of abnormalities are essential. In addition, many kinds of spontaneous ocular findings are well known in experimental animals. To differentiate treatment-related changes from spontaneous findings, mastering basic skills for ophthalmologic examinations and taking advantage of collection of background data are necessary. For ocular toxicity risk assessments, while an evaluation of "sight-threatening" effects is most critical matter, "quality of vision" related findings also should be considered. To extrapolate animal data to human, clinical significances of ocular toxicity findings should be evaluated based on considerations for "species differences", "safety margins", "reversibility", and "risk-benefit balance". In addition, a detailed recording of features of lesions is also important for an appropriate judgment of clinical significance of ocular findings. For preparation of histopathological specimens, careful sampling of organs and suitable selection of fixatives are important. To accurately orient ocular lesions in the specimen for histopathological examinations, securing close communications prior to necropsy among ophthalmologists, gross necropsy pathologists and histopathology technicians should be effective and helpful. It is impossible to detect all ocular changes in histopathological examinations; that is, there is a limitation in histopathological examinations. Therefore, for ocular toxicity risk assessments, comprehensive evaluation with pathological findings as well as other results of various examinations in toxicity studies should be considered. In conclusion, for ocular toxicity risk assessments, integrated judgments from all examination data in nonclinical toxicity studies are required. To achieve appropriate risk assessments which can be extrapolated to human, close communications and sharing of data regarding the eye are most important among toxicologists, clinical sign investigators, histopathology technicians and pathologists.
人类通常约80%的外部信息来自视觉。由于视力丧失会显著降低生活质量,因此对新药视觉毒性的风险评估极为重要。然而,国际人用药品注册技术协调会(ICH)关于新药非临床毒性研究的S4指南仅对眼科检查给出了简要说明,仅依据该指南提交的用于药物批准的数据,从眼部毒性风险评估的角度来看,并不总是被认为足够充分。眼睛是由许多具有特定功能的专门子器官组成的集合体,其对体内平衡的整体维持对视觉功能起着重要作用。当仅部分功能完整性丧失时,眼睛的整体功能通常可能会受到干扰。因此,了解这些子器官的解剖学和生理学知识可能有助于了解所观察到的眼部变化的机制。在非临床毒性研究的眼科检查中,了解每项检查的原理和特点至关重要。比较药物治疗前后的检查结果以及考虑物种差异、品系差异、年龄差异和异常的部位/程度是必不可少的。此外,在实验动物中存在许多种自发性眼部检查结果是众所周知的。为了区分与治疗相关的变化和自发性检查结果,掌握眼科检查的基本技能并利用背景数据的收集是必要的。对于眼部毒性风险评估,虽然对“威胁视力”影响的评估是最关键的问题,但与“视力质量”相关的检查结果也应予以考虑。为了将动物数据外推至人类,应基于对“物种差异”、“安全边际”、“可逆性”和“风险效益平衡”的考虑来评估眼部毒性检查结果的临床意义。此外,详细记录病变特征对于正确判断眼部检查结果的临床意义也很重要。对于组织病理学标本的制备,仔细的器官取样和合适的固定剂选择很重要。为了在组织病理学检查的标本中准确确定眼部病变的方位,在尸检前确保眼科医生、大体尸检病理学家和组织病理学技术人员之间的密切沟通将是有效且有帮助的。在组织病理学检查中不可能检测到所有的眼部变化;也就是说,组织病理学检查存在局限性。因此,对于眼部毒性风险评估,应考虑将病理检查结果与毒性研究中各种其他检查结果进行综合评估。总之,对于眼部毒性风险评估,需要对非临床毒性研究中的所有检查数据进行综合判断。为了实现能够外推至人类的适当风险评估,毒理学家、临床症状研究人员、组织病理学技术人员和病理学家之间关于眼睛的数据密切沟通和共享是最重要的。